Smart Connected Drug Delivery Devices Market Size & Share 2026-2035

Smart Connected Drug Delivery Devices Market Size

The global smart connected drug delivery devices market was valued at USD 603.9 million in 2025 and is projected to grow from USD 700 million in 2026 to USD 5.1 billion by 2035, expanding at a CAGR of 24.6%, according to the latest report published by Global Market Insights Inc. This substantial growth is driven by several key factors, including growing prevalence of chronic diseases, rising patient awareness about adherence to prescribed therapies and rapidly moving healthcare IT infrastructure.

Smart connected drug delivery devices are advanced drug administration systems equipped with connectivity technologies such as Bluetooth, NFC, or Wi‑Fi that enable real-time monitoring, data collection, and communication with digital healthcare platforms. These devices help track medication usage, improve treatment adherence, and provide healthcare professionals with actionable patient data. By integrating drug delivery with mobile applications, cloud platforms, and remote monitoring systems, smart connected drug delivery devices support personalized therapy management and enhance overall patient outcomes.

Leading companies in the smart connected drug delivery devices market include Insulet Corporation, Medtronic, Novo Nordisk, Ypsomed, and Tandem Diabetes Care. These companies are strengthening their market presence through continuous innovation in connected insulin delivery systems, smart injection technologies, and digitally enabled drug administration solutions. They are focused on enhancing medication adherence, improving dosing accuracy, and expanding connectivity capabilities through integration with mobile applications, cloud-based platforms, and remote patient monitoring systems. Furthermore, these market participants are investing in advanced automation, data-driven disease management, and personalized therapy solutions to broaden the application of smart connected drug delivery devices across diabetes care and other chronic disease management settings.

The market has increased from USD 422.4 million in 2022 and reached USD 519.6 million in 2024, with a historic growth rate of 10.9%. The rising global burden of chronic diseases, particularly diabetes, is a major driver of the smart connected drug delivery devices market. Chronic conditions require long-term medication management, continuous monitoring, and improved patient adherence, creating strong demand for connected drug delivery solutions that enable real-time tracking, automated dosing, and remote healthcare integration. Diabetes, one of the fastest-growing chronic diseases worldwide, exemplifies this trend. According to the International Diabetes Federation (IDF), approximately 589 million adults aged 20–79 were living with diabetes in 2024, and this number is projected to increase to 853 million by 2050, representing a substantial rise in the global patient population.

Additionally, the increasing adoption of machine learning (ML) and artificial intelligence (AI) is emerging as a significant driver for the smart connected drug delivery devices market. AI-powered drug delivery systems enhance treatment accuracy by analyzing patient health data, medication usage patterns, and disease progression to support personalized dosing and therapy management. Integrated with connected devices, ML algorithms can predict potential adherence issues, generate automated reminders, and provide real-time insights to healthcare professionals, improving patient outcomes. Furthermore, AI-enabled analytics facilitate remote monitoring by continuously tracking patient behavior and treatment effectiveness, reducing the need for frequent clinical visits. The growing emphasis on precision medicine and digital healthcare is encouraging manufacturers to incorporate advanced AI capabilities into connected insulin pens, wearable injectors, and infusion systems. As healthcare providers increasingly seek data-driven and patient-centric solutions, the integration of AI and ML technologies is expected to accelerate innovation, enhance operational efficiency, and drive widespread adoption of smart connected drug delivery devices worldwide.

Smart Connected Drug Delivery Devices Market Trends

• The rapid advancement of healthcare IT infrastructure is emerging as a significant trend in the smart connected drug delivery devices industry. Healthcare providers across the globe are increasingly investing in digital health platforms, electronic health records (EHRs), cloud-based data management systems, and interoperable healthcare networks. This transformation is creating an environment where smart drug delivery devices can seamlessly connect with broader healthcare ecosystems, enabling efficient data exchange and improved patient management.
• Additionally, the growing integration of connected drug delivery devices with healthcare IT systems is enhancing real-time monitoring and clinical decision-making. Data generated by connected insulin pens, wearable injectors, and infusion devices can be automatically transmitted to healthcare platforms, allowing clinicians to track medication adherence, optimize treatment regimens, and identify potential health risks more effectively.
• Furthermore, the expansion of telehealth and remote patient monitoring services is accelerating the demand for interoperable smart drug delivery solutions. As healthcare organizations increasingly rely on digital communication channels, connected devices are becoming essential tools for facilitating continuous patient engagement and enabling healthcare professionals to monitor treatment progress remotely.
• Moreover, advancements in cloud computing, data analytics, and cybersecurity technologies are strengthening the reliability and scalability of connected healthcare systems. Improved IT infrastructure supports the secure management of large volumes of patient data while enabling personalized treatment approaches. As healthcare systems continue their digital transformation journey, the synergy between advanced IT infrastructure and connected drug delivery technologies is expected to drive innovation and long-term market growth.

Smart Connected Drug Delivery Devices Market Analysis

Based on product, the market is bifurcated into connected sensors and integrated devices. The integrated devices segment dominated the market with the largest revenue share of 60.8% in 2025.

• Integrated devices are gaining widespread acceptance as they combine drug delivery and connectivity functionalities within a single platform, delivering a more seamless user experience. These devices are designed to automatically record dosing events, transmit treatment data, and support personalized therapy management without the need for external accessories.
• The shift toward connected care models and self-administration therapies is driving investment in integrated smart connected drug delivery devices. Advanced features such as automated dose tracking, remote monitoring, and direct integration with healthcare ecosystems are increasing their appeal among both patients and providers, supporting continued market expansion.
• The connected sensors segment accounted for USD 236.5 million in 2025 and is projected to expand to a CAGR of 24.7% from 2026 to 2035. Connected sensors are playing an increasingly important role in the evolution of smart connected drug delivery devices by enabling the capture and transmission of medication-related data without significantly altering existing drug delivery systems. These sensors can be attached to inhalers, pens, or injectors to monitor usage patterns, dosing frequency, and patient adherence in real time.
• Growing demand for cost-effective digital health solutions is accelerating the adoption of connected sensors across chronic disease management applications. Their ability to convert conventional drug delivery devices into connected healthcare tools allows manufacturers and healthcare providers to expand digital monitoring capabilities while minimizing device redesign requirements.
   

Based on technology, the smart connected drug delivery devices market is segmented into Bluetooth, near field communication, and Wi-Fi. The Bluetooth segment dominated the market with the largest revenue share of 47.6% in 2025.  

• Bluetooth technology continues to witness strong adoption in connected drug delivery devices owing to its ability to enable seamless communication between drug delivery systems and smartphones, tablets, and healthcare applications. The technology supports real-time transfer of dosing information, treatment records, and adherence data, allowing patients to actively manage their therapies while providing clinicians with continuous visibility into treatment progress.
• The growing penetration of smartphones and mobile health applications is further strengthening the adoption of Bluetooth-enabled devices. Manufacturers are increasingly integrating Bluetooth connectivity into smart insulin pens and wearable injectors to enhance user convenience, improve medication adherence, and support remote patient monitoring, making the technology a key enabler of digital healthcare delivery.
• The NFC segment accounted for USD 174.7 million in 2025 and is projected to expand at a CAGR of 24.6% from 2026 to 2035. NFC technology is gaining traction in the market due to its simplicity, security, and ease of use for device pairing and data exchange. The technology enables users to instantly connect drug delivery devices with smartphones or healthcare platforms by simply bringing compatible devices into proximity, eliminating complex setup procedures.
• Increasing emphasis on patient-centric care is encouraging the incorporation of NFC functionality into connected drug delivery solutions. The technology facilitates quick access to dosage history, device settings, and treatment information, supporting greater patient engagement while ensuring efficient data sharing between patients, caregivers, and healthcare professionals.
• The WiFi segment accounted for USD 141.5 million in 2025 and is projected to expand at a CAGR of 24.9% from 2026 to 2035. Wi‑Fi-enabled drug delivery devices are becoming increasingly important as healthcare systems place greater emphasis on remote care and continuous patient monitoring. Unlike short-range communication technologies, Wi‑Fi supports direct connectivity with cloud platforms and healthcare networks, enabling uninterrupted transmission of treatment data across broader geographic distances.
• The expansion of digital health ecosystems and cloud-based healthcare infrastructure is accelerating the deployment of Wi‑Fi-connected drug delivery solutions. These devices support advanced analytics, long-term patient monitoring, and integration with electronic health records, helping healthcare providers enhance treatment oversight and deliver more personalized therapeutic interventions.
   

Based on application, the smart connected drug delivery devices market is segmented into anaphylaxis, respiratory, cardiovascular, diabetes, hormone replacement, oncology, and other applications. The respiratory segment dominated the market with the largest revenue of USD 260.3 million in 2025.  

• Respiratory applications are witnessing substantial adoption of smart connected drug delivery devices as healthcare providers increasingly emphasize medication adherence and disease control in asthma and COPD management. Connected inhalers help track medication usage, generate adherence insights, and provide timely reminders, enabling patients to follow prescribed treatment regimens more effectively.
• For instance, according to the American Lung Association, approximately 44.2 million people in the United States had received an asthma diagnosis in 2022, representing a significant increase from 9.1% in 1999 to 13.5% in 2022, a rise of nearly 48%. This growing prevalence of respiratory conditions highlights the increasing demand for advanced drug delivery technologies and effective disease management solutions to improve treatment adherence, patient outcomes, and overall respiratory care.
• The anaphylaxis segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 24.5% over the forecast period. The use of smart connected drug delivery devices for anaphylaxis management is increasing as healthcare systems focus on improving emergency treatment preparedness. Connected auto-injectors can provide administration guidance, usage tracking, and alerts that help patients and caregivers respond more effectively during critical situations.
• Rising awareness regarding severe allergic reactions and the importance of rapid epinephrine administration is encouraging innovation in connected emergency drug delivery solutions.
• The cardiovascular segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 24.9% over the forecast period.  In cardiovascular care, smart connected drug delivery devices are gaining traction due to the growing need for precise and long-term medication management. Connected delivery platforms enable continuous monitoring of therapy adherence, helping support treatment programs for patients requiring regular injectable cardiovascular medications.
• For instance, according to the Centers for Disease Control and Prevention (CDC), 919,032 people in the U.S. died from cardiovascular disease in 2023, meaning that approximately one out of every three deaths was attributed to cardiovascular conditions. This substantial mortality burden highlights the growing need for effective disease management solutions, advanced monitoring technologies, and innovative drug delivery systems to support timely treatment, improve medication adherence, and reduce cardiovascular-related health risks.
• The increasing shift toward data-driven healthcare is creating opportunities for connected cardiovascular drug delivery solutions. Real-time treatment information assists healthcare professionals in optimizing medication strategies and improving overall disease management efficiency.
• The diabetes segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 25.1% over the forecast period. Diabetes remains a major application area for smart connected drug delivery devices, driven by the increasing number of patients requiring routine insulin administration. Connected insulin pens, wearable delivery systems, and smart injectors provide automated dose recording and therapy tracking, making day-to-day disease management more efficient.
• Expanding adoption of digital diabetes management ecosystems is further accelerating growth within this segment. The ability to integrate dosing information with glucose monitoring platforms enables more personalized treatment approaches and enhances patient engagement in self-care activities.

Based on end use, the smart connected drug delivery devices market is segmented into hospitals, clinics, home care settings, and other end users. The home care settings segment dominated the market with the largest revenue of USD 244.5 million in 2025.

• Home care settings are emerging as a key growth area for smart connected drug delivery devices due to the growing preference for self-administration and home-based treatment. Patients increasingly favor technologies that offer convenience, flexibility, and real-time guidance without requiring regular visits to healthcare facilities.
• The expansion of remote patient monitoring and telehealth services is further driving adoption in home environments. Smart connected drug delivery devices enable automatic data sharing with healthcare providers, helping ensure treatment adherence, facilitating proactive disease management, and supporting better long-term health outcomes.
• Hospitals segment is anticipated to grow at a CAGR of 24.4% over the forecast period. Hospitals are increasingly adopting smart connected drug delivery devices to improve medication accuracy, reduce administration errors, and support data-driven patient care. The ability of these devices to integrate with hospital information systems and electronic medical records enables healthcare professionals to track dosing patterns and patient responses more efficiently.
• Growing patient volumes and the rising prevalence of chronic diseases are encouraging hospitals to invest in connected treatment technologies that streamline clinical workflows. The use of real-time monitoring capabilities allows care teams to optimize therapy management, support timely interventions, and enhance overall treatment outcomes.
• The clinics segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 24.6% over the forecast period. The adoption of smart connected drug delivery devices in clinics is expanding as healthcare providers seek efficient solutions for managing long-term therapies. These devices facilitate precise medication administration while enabling clinicians to monitor patient adherence and treatment effectiveness through connected digital platforms. As outpatient care continues to grow, clinics are increasingly leveraging connected drug delivery technologies to improve patient engagement and reduce the burden of frequent follow-up visits.

North America Smart Connected Drug Delivery Devices Market

The North America region accounted for 43.4% of the global market in 2025. The smart connected drug delivery devices industry in North America is experiencing robust expansion.

• The U.S. market was valued at USD 162.2 million and USD 176.5 million in 2022 and 2023, respectively. The market size reached USD 228.9 million in 2025, growing from USD 197.8 million in 2024, and is anticipated to grow at a CAGR of 24.1% from 2026 to 2035.
• The growing incidence of chronic diseases, particularly diabetes, is a major driver of the North America smart connected drug delivery devices market. Chronic conditions require continuous medication administration, adherence monitoring, and long-term disease management, increasing the demand for connected drug delivery solutions that enable real-time tracking and personalized therapy management. According to the Centers for Disease Control and Prevention (CDC), an estimated 40.1 million people in the United States were living with diagnosed or undiagnosed diabetes in 2023. Among these, 29.1 million individuals had diagnosed diabetes, while approximately 11 million people remained undiagnosed, highlighting the substantial patient population requiring ongoing treatment and monitoring.
• The rising diabetes burden is accelerating the adoption of smart connected drug delivery devices such as connected insulin pens, wearable injectors, and smart insulin management systems. These technologies help improve medication adherence, support remote patient monitoring, and provide healthcare professionals with real-time treatment data for more effective disease management. Furthermore, the increasing focus on reducing complications associated with chronic diseases and enhancing patient outcomes is encouraging healthcare providers and patients to adopt connected drug delivery solutions across North America, thereby fueling market growth.

Europe Smart Connected Drug Delivery Devices Market

Europe market accounted for USD 144.6 million in 2025 and is anticipated to show lucrative growth over the forecast period.

• The rising prevalence of chronic diseases across Europe is creating strong demand for smart connected drug delivery devices, as healthcare systems increasingly focus on improving long-term disease management and treatment adherence. Chronic conditions often require continuous medication administration and regular monitoring, prompting healthcare providers to adopt digital solutions that enable more effective and patient-centric care. Cardiovascular diseases (CVDs) remain a major healthcare challenge in the region, significantly contributing to hospitalization rates, healthcare expenditures, and mortality.
• Germany exemplifies this growing burden, with cardiovascular diseases accounting for approximately 40% of all deaths in the country. The substantial impact of CVDs is encouraging greater adoption of connected drug delivery technologies that support medication compliance, remote patient monitoring, and real-time treatment tracking. Furthermore, the increasing emphasis on preventive care and digital health integration is accelerating the deployment of smart connected drug delivery devices across European healthcare settings. These solutions help clinicians gain better visibility into patient treatment patterns while enabling individuals to manage chronic conditions more effectively, thereby supporting continued market growth throughout the region.

Asia Pacific Smart Connected Drug Delivery Devices Market

The Asia Pacific region is projected to show a lucrative growth of about 25.1% during the forecast period.

• The growing adoption of telehealth platforms integrated with augmented reality (AR) and virtual reality (VR) technologies is emerging as a key driver for the Asia Pacific market. Healthcare providers across the region are increasingly leveraging advanced digital health solutions to improve patient engagement, expand access to care, and enhance the management of chronic diseases. The integration of AR/VR capabilities into telehealth ecosystems is creating more interactive and immersive treatment experiences, supporting better patient education and medication compliance.
• The increasing deployment of telemedicine services, particularly in densely populated and geographically dispersed regions, is encouraging greater utilization of smart connected drug delivery devices. These devices facilitate real-time sharing of treatment data with healthcare professionals, while AR/VR-enabled platforms can assist patients in understanding device usage, injection techniques, and therapy protocols. Furthermore, rising investments in digital healthcare infrastructure and the growing acceptance of remote care models are accelerating the convergence of telehealth and connected drug delivery technologies. This trend is enabling more efficient disease management, improving treatment adherence, and creating new growth opportunities for the Asia Pacific market.

Latin America Smart Connected Drug Delivery Devices Market 

The Latin America market is experiencing robust growth over the analysis timeframe.

• The ongoing advancement of healthcare IT infrastructure across Latin America is significantly supporting the growth of the market. Healthcare organizations are increasingly adopting digital health platforms, electronic medical records, cloud-based systems, and connected care technologies to improve patient management and healthcare service delivery. This digital transformation is creating a stronger foundation for the integration of connected drug delivery solutions into routine clinical practice.
• Improved healthcare connectivity is enabling smart connected drug delivery devices to seamlessly exchange treatment information with healthcare providers, allowing greater visibility into medication use and patient adherence. In addition, the expansion of digital health networks and telemedicine services is encouraging wider adoption of connected therapeutic devices that facilitate remote monitoring and personalized treatment management. As Latin American healthcare systems continue to modernize, the growing interoperability between digital platforms and smart drug delivery technologies is expected to enhance treatment efficiency, support better clinical outcomes, and accelerate market growth across the region.

Middle East and Africa Smart Connected Drug Delivery Devices Market 

The Middle East and Africa (MEA) market is experiencing robust growth over the analysis timeframe.

• The growing awareness among patients regarding the importance of medication adherence is becoming a key driver for the Middle East & Africa market. As chronic diseases such as diabetes, cardiovascular disorders, and respiratory conditions become more prevalent across the region, patients are increasingly recognizing the need to follow prescribed treatment regimens consistently to achieve better health outcomes and minimize disease-related complications.
• This shift in patient behavior is encouraging the adoption of smart connected drug delivery devices that offer features such as dose reminders, treatment tracking, real-time monitoring, and digital adherence support. These technologies help patients maintain accurate medication schedules while providing healthcare professionals with valuable insights into therapy compliance. Furthermore, growing health literacy levels, expanding access to digital healthcare services, and increasing utilization of mobile health applications are strengthening the acceptance of connected drug delivery solutions. As patients become more proactive in managing their health, the demand for smart connected drug delivery devices is expected to rise steadily across the Middle East and Africa.

Smart Connected Drug Delivery Devices Market Share

• The top five players, Insulet Corporation, Medtronic, Novo Nordisk, Ypsomed, and Tandem Diabetes Care, collectively account for a 45% share of the smart connected drug delivery devices industry. Their strong market position is supported by extensive portfolios of connected insulin delivery systems, smart injection devices, and digital diabetes management solutions. These companies benefit from continuous investments in connectivity technologies, automated drug delivery capabilities, remote patient monitoring integration, and broad commercialization networks. Furthermore, their focus on enhancing medication adherence, improving treatment outcomes, and expanding interoperability with digital healthcare ecosystems continues to strengthen their competitive presence in the global smart connected drug delivery devices market.
• Manufacturers of smart connected drug delivery devices, digital health companies, and pharmaceutical organizations are increasingly focusing on technological innovations to enhance medication adherence, treatment monitoring, and patient engagement. Additionally, advancements in Bluetooth connectivity, cloud-based healthcare platforms, mobile health applications, artificial intelligence, and remote patient monitoring technologies are improving device functionality and data accessibility. Continuous investments in digital therapeutics, connected healthcare ecosystems, and next-generation drug delivery solutions are supporting the broader adoption of smart connected drug delivery devices across hospitals, clinics, and home care settings.
• Market participants, including drug delivery device manufacturers, pharmaceutical companies, healthcare technology providers, and healthcare organizations, are increasingly strengthening strategic partnerships to accelerate the development and commercialization of smart connected drug delivery devices. Collaborations between pharmaceutical firms and device developers are enabling the integration of connectivity features into inhalers, insulin pens, autoinjectors, and wearable injectors, supporting improved treatment adherence and patient outcomes. Furthermore, partnerships with digital health companies, telehealth providers, research institutions, and healthcare systems are facilitating the development of remote monitoring platforms, data analytics solutions, and patient management programs. These initiatives are enhancing the integration of connected care into routine clinical practice, expanding access to personalized treatment management, and contributing to the growing adoption of smart connected drug delivery devices across global healthcare markets.

Smart Connected Drug Delivery Devices Market Companies

Few of the prominent players operating in the smart connected drug delivery devices industry include:

• Adherium
• Aptar Pharma
• Becton, Dickinson and Company
• Bayer
• Biocorp
• Eli Lilly and Company
• Enable Injections
• Gerresheimer
• Insulet Corporation
• Medtronic
• Nemera
• Novo Nordisk
• Philips Medisize
• SHL Medical
• Tandem Diabetes Care
• West Pharmaceutical Services
• Ypsomed

• Insulet Corporation

Insulet Corporation is a prominent participant in the smart connected drug delivery devices market, leveraging advanced connectivity and automated insulin delivery technologies to support real-time diabetes management, enhance treatment adherence, and improve patient engagement through data-driven care.

• Tandem Diabetes Care

Tandem Diabetes Care strengthens the market through its connected insulin delivery technologies that combine automated dosing with advanced digital connectivity. The company’s solutions support personalized diabetes management and enhance coordination between patients and healthcare providers.

Smart Connected Drug Delivery Devices Industry News:

• In May 2024, Enable Injections expanded its strategic partnership with Roche through a new collaboration agreement that granted Roche a worldwide exclusive license to develop and commercialize combinations of Enable’s enFuse wearable drug delivery technology with selected Roche molecules. Under the agreement, Enable remained responsible for the clinical and commercial manufacturing and supply of the enFuse system, while Roche leveraged the platform for specific drug development programs. This partnership strengthened Enable’s position in the smart drug delivery devices market, enhancing its commercial visibility, expanding adoption opportunities for enFuse technology, and reinforcing its credibility among global pharmaceutical companies.

The smart connected drug delivery devices market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Connected sensors

  • Connected inhalation sensors
  • Connected injectable sensors
• Integrated devices
  • Integrated inhalation devices
  • Integrated injectable devices

Market, By Technology

• Bluetooth
• Near field communication
• Wi-Fi

Market, By Application

• Anaphylaxis
• Respiratory
• Cardiovascular
• Diabetes
• Hormone replacement
• Oncology
• Other applications

Market, By End Use

• Hospitals
• Clinics
• Home care settings
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE